{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:18:24Z","timestamp":1784308704821,"version":"3.55.0"},"reference-count":43,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: In clinical practice, bone mineral density (BMD) determined by dual-energy x-ray absorptiometry is used to monitor response to osteoporosis therapy. However, 1 to 2 yr are usually required to assess patients\u2019 BMD responses. The possibility of earlier indicators of a response or nonresponse to treatment, such as changes in bone turnover markers (BTMs), is of interest to physicians and patients.<\/jats:p>\n               <jats:p>Methods: In this post hoc analysis of women treated with once-weekly bisphosphonates, we examined the association of tertile percentage change from baseline in BTMs at 3 or 6 months and association of several baseline clinical characteristics with 24-month percentage change from baseline in BMD and with percentage of patients showing BMD nonresponse (defined as BMD loss at two or more of four sites) at 24 months. Multivariable analysis was performed to determine which factors were independently associated with BMD nonresponse.<\/jats:p>\n               <jats:p>Results: Patients in the tertile with the greatest decrease in each of the BTMs had the greatest mean increase in BMD and the lowest percentage of BMD nonresponders at 24 months. Several characteristics were independently associated with BMD nonresponse, including smaller 3-month reductions from baseline in serum C-terminal telopeptide of type 1 collagen, bone-specific alkaline phosphatase, and N-terminal propeptide of type 1 procollagen; younger age of menopause; a family history of osteoporosis; and higher baseline trochanteric BMD. Baseline BTMs were not predictive of 24-month BMD response to therapy. The strongest associations were for changes in BTMs with treatment.<\/jats:p>\n               <jats:p>Conclusion: In groups of patients, short-term changes in markers of bone turnover appear to be predictors of longer term BMD response and nonresponse to bisphosphonate therapy.<\/jats:p>","DOI":"10.1210\/jc.2008-1122","type":"journal-article","created":{"date-parts":[[2009,1,14]],"date-time":"2009-01-14T01:35:07Z","timestamp":1231896907000},"page":"1097-1103","source":"Crossref","is-referenced-by-count":22,"title":["Prediction of Changes in Bone Mineral Density in Postmenopausal Women Treated with Once-Weekly Bisphosphonates"],"prefix":"10.1210","volume":"94","author":[{"given":"Sherri-Ann M.","family":"Burnett-Bowie","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital (S.M.B.), Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Saag","sequence":"additional","affiliation":[{"name":"University of Alabama (K.S.), Birmingham, Alabama 35294"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Sebba","sequence":"additional","affiliation":[{"name":"Arthritis Associates (A.S.), Palm Harbor, Florida 34684"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"de Papp","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. (A.E.d.P., E.C., E.R.), North Wales, Pennsylvania 19454"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erluo","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. (A.E.d.P., E.C., E.R.), North Wales, Pennsylvania 19454"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. (A.E.d.P., E.C., E.R.), North Wales, Pennsylvania 19454"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Greenspan","sequence":"additional","affiliation":[{"name":"University of Pittsburgh (S.L.G.), Pittsburgh, Pennsylvania 15260"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071615595369100_R1","unstructured":"2007\n          National Osteoporosis Foundation\n          web site. http:\/\/www.nof.org\/advocacy\/prevalence\/indication"},{"key":"2020071615595369100_R2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S8756-3282(00)00272-6","article-title":"Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women.","volume":"26","author":"Bjarnason","year":"2000","journal-title":"Bone"},{"key":"2020071615595369100_R3","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2020071615595369100_R4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S8756-3282(00)00271-4","article-title":"Monitoring individual response to hormone replacement therapy with bone markers.","volume":"26","author":"Delmas","year":"2000","journal-title":"Bone"},{"key":"2020071615595369100_R5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"2020071615595369100_R6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2020071615595369100_R7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2020071615595369100_R8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","article-title":"Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.","volume":"24","author":"Ravn","year":"1999","journal-title":"Bone"},{"key":"2020071615595369100_R9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"2020071615595369100_R10","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615595369100_R11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve-month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis.","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporos Int"},{"key":"2020071615595369100_R12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020071615595369100_R13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk.","volume":"19","author":"Sarkar","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071615595369100_R14","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2020071615595369100_R15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density.","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615595369100_R16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.","volume":"7","author":"Watts","year":"2004","journal-title":"J Clin Densitom"},{"key":"2020071615595369100_R17","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1185\/030079904X16768","article-title":"Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.","volume":"20","author":"Sebba","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"2020071615595369100_R18","unstructured":"2007\n          International Society of Clinical Densitometry\n          web site. http:\/\/www.iscd.org"},{"key":"2020071615595369100_R19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.283.10.1318","article-title":"Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.","volume":"283","author":"Cummings","year":"2000","journal-title":"JAMA"},{"issue":"Suppl 6","key":"2020071615595369100_R20","first-page":"S2","article-title":"The use of biochemical markers of bone turnover in osteoporosis","volume":"11","author":"Delmas","year":"2000","journal-title":"Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int"},{"key":"2020071615595369100_R21","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1210\/jc.2004-1091","article-title":"Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615595369100_R22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2020071615595369100_R23","first-page":"3537","article-title":"Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women.","volume":"85","author":"Greenspan","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615595369100_R24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9343(96)00387-7","article-title":"Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.","volume":"102","author":"Chesnut III","year":"1997","journal-title":"Am J Med"},{"key":"2020071615595369100_R25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S8756-3282(98)00044-1","article-title":"Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.","volume":"22","author":"Ravn","year":"1998","journal-title":"Bone"},{"key":"2020071615595369100_R26","first-page":"1904","article-title":"The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.","volume":"82","author":"Rosen","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615595369100_R27","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1210\/jc.2005-1712","article-title":"Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.","volume":"91","author":"Bauer","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615595369100_R28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071615595369100_R29","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1210\/jc.2005-2602","article-title":"Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.","volume":"91","author":"Bonnick","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615595369100_R30","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bone.2007.01.008","article-title":"A cross-sectional study of bone turnover markers in healthy premenopausal women.","volume":"40","author":"de Papp","year":"2007","journal-title":"Bone"},{"key":"2020071615595369100_R31","doi-asserted-by":"crossref","volume-title":"Baseline characteristics of non-responders to bisphosphonate therapy in the FACT Study","author":"Saag","DOI":"10.1016\/j.jocd.2006.04.105"},{"key":"2020071615595369100_R32","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2020071615595369100_R33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","article-title":"Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.","volume":"21","author":"Bauer","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2020071615595369100_R34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s002239900170","article-title":"The correlation of bone mineral density and biochemical markers to fracture risk","volume":"59","author":"Adachi","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"2020071615595369100_R35","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/jbmr.5650101127","article-title":"Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women.","volume":"10","author":"Akesson","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2020071615595369100_R36","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1359\/jbmr.2003.18.2.312","article-title":"Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction.","volume":"18","author":"Melton III","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020071615595369100_R37","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1359\/jbmr.1999.14.8.1404","article-title":"Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures.","volume":"14","author":"Bauer","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020071615595369100_R38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bone.2003.10.004","article-title":"Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.","volume":"34","author":"Reginster","year":"2004","journal-title":"Bone"},{"key":"2020071615595369100_R39","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.","volume":"20","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071615595369100_R40","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1172\/JCI116138","article-title":"Estrogen status and heredity are major determinants of premenopausal bone mass.","volume":"90","author":"Armamento-Villareal","year":"1992","journal-title":"J Clin Invest"},{"key":"2020071615595369100_R41","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1056\/NEJM198903023200903","article-title":"Reduced bone mass in daughters of women with osteoporosis.","volume":"320","author":"Seeman","year":"1989","journal-title":"N Engl J Med"},{"key":"2020071615595369100_R42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jbmr.5650090304","article-title":"Influence of early age at menopause on vertebral bone mass.","volume":"9","author":"Pouilles","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"Suppl 6","key":"2020071615595369100_R43","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980070004","article-title":"Preanalytical variability of biochemical markers of bone turnover","volume":"11","author":"Hannon","year":"2000","journal-title":"Osteoporos Int"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/4\/1097\/10806540\/jcem1097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/4\/1097\/10806540\/jcem1097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:04:44Z","timestamp":1594955084000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/4\/1097\/2596225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-1122","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,1]]}}}